• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·7575.TWO
Share

Amed Co., Ltd. Stocks

NT$ 10.05Last Updated 24.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 10.24M

NT$ 10.05
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Amed Co., Ltd., based in New Taipei City, Taiwan, operates as a developer, manufacturer, and distributor of medical equipment within the region. Established in 2008, the company offers a diverse portfolio of products. Its wound care segment features HERADERM-branded dressing products, along with Genadyne negative pressure wound therapy systems specifically engineered to deliver continuous 24-hour oxygen to wounds, and Natrox wound treatment systems. Beyond wound care, Amed's offerings also include Naldebain, a line of injections providing extended pain relief for up to seven days. Furthermore, the company provides POLYSITE pressure injectable implantable port kits and easyEndo universal linear cutting staplers.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 04:30

Paramount has put its merger with Warner Bros. on hold for nearly a year

25.07.2026 02:56

Trump Threatened the European Union with New Tariffs Over Google's Billion-Dollar Fine

25.07.2026 02:12

Anthropic has introduced an affordable AI model for everyday tasks

25.07.2026 01:30

"FOMO Is Turning Into a Fear of Overinvesting": Nasdaq Lost More Than 2% Over the Week

25.07.2026 00:15

The YOLO strategy has backfired: traders' favorites are on track for their worst month in four years

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026